Primary sclerosing cholangitis

A review and update on therapeutic developments

James H. Tabibian, Keith D. Lindor

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease characterized by fibro-obliterative inflammation of the hepatic bile ducts. In a clinically significant proportion of patients, PSC progresses to cirrhosis, end-stage liver disease, and in some cases, cholangiocarcinoma. Despite clinical trials of nearly 20 different pharmacotherapies over several decades, safe and effective medical therapy, albeit critically needed, remains to be established. PSC is pathogenically complex, with genetic, immune, enteric microbial, environmental and other factors being potentially involved and, thus, not surprisingly, it manifests as a clinically heterogeneous disease with a relatively unpredictable course. It is likely that this complexity and clinical heterogeneity are responsible for the negative results of clinical trials, but novel insights about and approaches to PSC may shift this trend. The authors herein provide a review of previously tested pharmacologic agents, discuss emerging fundamental concepts and present viewpoints regarding how identifying therapies for PSC may evolve over the next several years.

Original languageEnglish (US)
Pages (from-to)103-114
Number of pages12
JournalExpert Review of Gastroenterology and Hepatology
Volume7
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Clinical Trials
Therapeutics
Common Hepatic Duct
End Stage Liver Disease
Cholangiocarcinoma
Bile Ducts
Liver Diseases
Fibrosis
Inflammation
Drug Therapy

Keywords

  • antibacterial agents
  • bile duct diseases
  • cholangiography
  • cholangiopancreatography
  • endoscopic retrograde
  • enterohepatic circulation
  • fibrosis
  • genes
  • magnetic resonance imaging
  • ras
  • TOR serine-threonine kinases

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Primary sclerosing cholangitis : A review and update on therapeutic developments. / Tabibian, James H.; Lindor, Keith D.

In: Expert Review of Gastroenterology and Hepatology, Vol. 7, No. 2, 02.2013, p. 103-114.

Research output: Contribution to journalReview article

@article{794ddface8a7407e9d255685a1902c21,
title = "Primary sclerosing cholangitis: A review and update on therapeutic developments",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease characterized by fibro-obliterative inflammation of the hepatic bile ducts. In a clinically significant proportion of patients, PSC progresses to cirrhosis, end-stage liver disease, and in some cases, cholangiocarcinoma. Despite clinical trials of nearly 20 different pharmacotherapies over several decades, safe and effective medical therapy, albeit critically needed, remains to be established. PSC is pathogenically complex, with genetic, immune, enteric microbial, environmental and other factors being potentially involved and, thus, not surprisingly, it manifests as a clinically heterogeneous disease with a relatively unpredictable course. It is likely that this complexity and clinical heterogeneity are responsible for the negative results of clinical trials, but novel insights about and approaches to PSC may shift this trend. The authors herein provide a review of previously tested pharmacologic agents, discuss emerging fundamental concepts and present viewpoints regarding how identifying therapies for PSC may evolve over the next several years.",
keywords = "antibacterial agents, bile duct diseases, cholangiography, cholangiopancreatography, endoscopic retrograde, enterohepatic circulation, fibrosis, genes, magnetic resonance imaging, ras, TOR serine-threonine kinases",
author = "Tabibian, {James H.} and Lindor, {Keith D.}",
year = "2013",
month = "2",
doi = "10.1586/egh.12.80",
language = "English (US)",
volume = "7",
pages = "103--114",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Primary sclerosing cholangitis

T2 - A review and update on therapeutic developments

AU - Tabibian, James H.

AU - Lindor, Keith D.

PY - 2013/2

Y1 - 2013/2

N2 - Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease characterized by fibro-obliterative inflammation of the hepatic bile ducts. In a clinically significant proportion of patients, PSC progresses to cirrhosis, end-stage liver disease, and in some cases, cholangiocarcinoma. Despite clinical trials of nearly 20 different pharmacotherapies over several decades, safe and effective medical therapy, albeit critically needed, remains to be established. PSC is pathogenically complex, with genetic, immune, enteric microbial, environmental and other factors being potentially involved and, thus, not surprisingly, it manifests as a clinically heterogeneous disease with a relatively unpredictable course. It is likely that this complexity and clinical heterogeneity are responsible for the negative results of clinical trials, but novel insights about and approaches to PSC may shift this trend. The authors herein provide a review of previously tested pharmacologic agents, discuss emerging fundamental concepts and present viewpoints regarding how identifying therapies for PSC may evolve over the next several years.

AB - Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, idiopathic liver disease characterized by fibro-obliterative inflammation of the hepatic bile ducts. In a clinically significant proportion of patients, PSC progresses to cirrhosis, end-stage liver disease, and in some cases, cholangiocarcinoma. Despite clinical trials of nearly 20 different pharmacotherapies over several decades, safe and effective medical therapy, albeit critically needed, remains to be established. PSC is pathogenically complex, with genetic, immune, enteric microbial, environmental and other factors being potentially involved and, thus, not surprisingly, it manifests as a clinically heterogeneous disease with a relatively unpredictable course. It is likely that this complexity and clinical heterogeneity are responsible for the negative results of clinical trials, but novel insights about and approaches to PSC may shift this trend. The authors herein provide a review of previously tested pharmacologic agents, discuss emerging fundamental concepts and present viewpoints regarding how identifying therapies for PSC may evolve over the next several years.

KW - antibacterial agents

KW - bile duct diseases

KW - cholangiography

KW - cholangiopancreatography

KW - endoscopic retrograde

KW - enterohepatic circulation

KW - fibrosis

KW - genes

KW - magnetic resonance imaging

KW - ras

KW - TOR serine-threonine kinases

UR - http://www.scopus.com/inward/record.url?scp=84873120585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873120585&partnerID=8YFLogxK

U2 - 10.1586/egh.12.80

DO - 10.1586/egh.12.80

M3 - Review article

VL - 7

SP - 103

EP - 114

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 2

ER -